Clinical Trial: Effect of Anti CD20 in Pemphigus Desease

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Traitment of Patients Presenting Pemphigus With Anti CD20 (Mabthera).

Brief Summary: to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.

Detailed Summary:
Sponsor: University Hospital, Rouen

Current Primary Outcome: primary end-point was the rate of CR three months after the last infusion of Rituximab

Original Primary Outcome:

Current Secondary Outcome:

  • secondary end-points were :
  • rate of CR during the study period
  • time from the start of Rituximab to CR
  • number and length of time to relapses
  • treatment tolerance


Original Secondary Outcome:

Information By: University Hospital, Rouen

Dates:
Date Received: September 13, 2005
Date Started: June 2003
Date Completion:
Last Updated: June 17, 2013
Last Verified: June 2013